Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05488964
Other study ID # 479236
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date March 1, 2026

Study information

Verified date August 2023
Source Norwegian University of Science and Technology
Contact Trine Moholdt, PhD
Phone +4797098594
Email trine.moholdt@ntnu.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this trial is to investigate whether regular endurance exercise during the lactation period will influence breastmilk composition among individuals with overweight/obesity, and secondarily to assess if such changes impact the growth and health of the infants.


Recruitment information / eligibility

Status Recruiting
Enrollment 62
Est. completion date March 1, 2026
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female - Aged 18 years or older - Body mass index = 25 kg/m2 pre-pregnancy and/or BMI = 28 kg/m2 postpartum - Given birth to a singleton term (after 37 weeks + 0 days) baby - 6-7 weeks postpartum at time of inclusion - Exclusively breastfeeding the baby (no other foods are given) and intend to continue this practice for = 8 weeks at inclusion - Understands oral and written Norwegian Exclusion Criteria: - On-going pregnancy - Known type 1 or type 2 diabetes - Known cardiovascular disease - High intensity exercise more than twice weekly the last three months before inclusion and/or an intention to start regular endurance training within the next 8 weeks at baseline

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
Supervised endurance training with moderate-to-high intensity 3-4 times weekly.

Locations

Country Name City State
Norway Dept Circulation and Medical Imaging, EXCAR Exercise Lab Trondheim

Sponsors (1)

Lead Sponsor Collaborator
Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Exercise adherence Number of sessions completed (logbook) 0 to 8 weeks
Other Exercise compliance Heart rate during exercise (heart rate monitor) 0 to 8 weeks
Primary Breastmilk human milk oligosaccharide (HMO) 3'sialyllactose (3'SL) Relative concentration of 3'SL in breastmilk 0 to 8 weeks
Secondary Breastmilk human milk oligosaccharide (HMO) 3'sialyllactose (3'SL) Relative concentration of 3'SL in breastmilk 0 to 4 weeks
Secondary Breastmilk metabolites Relative concentrations of metabolites in breastmilk determined using untargeted metabolomics profiling (mass spectrometry) 0 to 8 weeks
Secondary Breastmilk metabolites Relative concentrations of metabolites in breastmilk determined using untargeted metabolomics profiling (mass spectrometry) 0 to 4 weeks
Secondary Breastmilk microRNA RNA sequencing 0 to 8 weeks
Secondary Breastmilk microRNA RNA sequencing 0 to 4 weeks
Secondary Maternal insulin sensitivity Homeostatic model assessment of insulin resistance (HOMA-IR) 0 to 8 weeks
Secondary Maternal fasting circulating insulin C-peptide concentrations From fasting venous blood sampling 0 to 8 weeks
Secondary Maternal fasting circulating glucose concentrations From fasting venous blood sampling After 9 months from baseline
Secondary Maternal circulating total cholesterol concentrations From fasting venous blood sampling 0 to 8 weeks
Secondary Maternal circulating total cholesterol concentrations From fasting venous blood sampling After 9 months from baseline
Secondary Maternal circulating high-density lipoprotein (HDL) concentrations From fasting venous blood sampling 0 to 8 weeks
Secondary Maternal circulating high-density lipoprotein (HDL) concentrations From fasting venous blood sampling After 9 months from baseline
Secondary Maternal circulating low-density lipoprotein (LDL) concentrations From fasting venous blood sampling 0 to 8 weeks
Secondary Maternal circulating low-density lipoprotein (LDL) concentrations From fasting venous blood sampling After 9 months from baseline
Secondary Maternal circulating triglycerides concentrations From fasting venous blood sampling 0 to 8 weeks
Secondary Maternal circulating triglycerides concentrations From fasting venous blood sampling After 9 months from baseline
Secondary Maternal glycated hemoglobin (HbA1c) From fasting venous blood sampling 0 to 8 weeks
Secondary Maternal glycated hemoglobin (HbA1c) From fasting venous blood sampling After 9 months from baseline
Secondary Maternal circulating high-sensitivity c-reactive protein From fasting venous blood sampling 0 to 8 weeks
Secondary Maternal circulating high-sensitivity c-reactive protein From fasting venous blood sampling After 9 months from baseline
Secondary Maternal total body mass Impedance scale 0 to 8 weeks
Secondary Maternal total body mass Impedance scale After 9 months from baseline
Secondary Maternal fat mass Impedance scale 0 to 8 weeks
Secondary Maternal fat mass Impedance scale After 9 months from baseline
Secondary Maternal fat-free mass Impedance scale 0 to 8 weeks
Secondary Maternal fat-free mass Impedance scale After 9 months from baseline
Secondary Maternal visceral fat area Impedance scale 0 to 8 weeks
Secondary Maternal visceral fat area Impedance scale After 9 months from baseline
Secondary Maternal bone mass Impedance scale 0 to 8 weeks
Secondary Maternal bone mass Impedance scale After 9 months from baseline
Secondary Maternal waist circumference Measuring tape 0 to 8 weeks
Secondary Maternal waist circumference Measuring tape After 9 months from baseline
Secondary Maternal cardiorespiratory fitness Maximum oxygen uptake via direct gas exchange 0 to 8 weeks
Secondary Maternal cardiorespiratory fitness Maximum oxygen uptake via direct gas exchange After 9 months from baseline
Secondary Maternal systolic blood pressure Automatic cuff 0 to 8 weeks
Secondary Maternal systolic blood pressure Automatic cuff After 9 months from baseline
Secondary Maternal diastolic blood pressure Automatic cuff 0 to 8 weeks
Secondary Maternal diastolic blood pressure Automatic cuff After 9 months from baseline
Secondary Maternal nutrition Diet diary completed for four days at baseline and at study completion 0 to 8 weeks
Secondary Maternal physical activity Number of steps per week, self-reported (questionnaire) 0 to 8 weeks
Secondary Maternal physical activity Number of steps per week, self-reported (questionnaire) After 9 months from baseline
Secondary Maternal physical activity Minutes of moderate-intensity physical activity per week, self-reported (questionnaire) 0 to 8 weeks
Secondary Maternal physical activity Minutes of high-intensity physical activity per week, self-reported (questionnaire) After 9 months from baseline
Secondary Maternal psychological well-being Self-reported (questionnaire) 0 to 8 weeks
Secondary Maternal psychological well-being Self-reported (questionnaire) After 9 months from baseline
Secondary Infant total body mass Impedance scale 0 to 8 weeks
Secondary Infant total body mass Impedance scale After 9 months from baseline
Secondary Infant fat mass Impedance scale 0 to 8 weeks
Secondary Infant fat mass Impedance scale After 9 months from baseline
Secondary Infant muscle mass Impedance scale 0 to 8 weeks
Secondary Infant muscle mass Impedance scale After 9 months from baseline
Secondary Infant bone density Impedance scale 0 to 8 weeks
Secondary Infant bone density Impedance scale After 9 months from baseline
Secondary Infant hydration status Impedance scale 0 to 8 weeks
Secondary Infant hydration status Impedance scale After 9 months from baseline
Secondary Infant total body mass (trajectories) From health records Infant age 4 weeks
Secondary Infant length (trajectories) From health records Infant age 4 weeks
Secondary Infant head circumference (trajectories) From health records Infant age 4 weeks
Secondary Infant total body mass (trajectories) From health records Infant age 6 weeks
Secondary Infant length (trajectories) From health records Infant age 6 weeks
Secondary Infant head circumference (trajectories) From health records Infant age 6 weeks
Secondary Infant total body mass (trajectories) From health records Infant age 3 months
Secondary Infant length (trajectories) From health records Infant age 3 months
Secondary Infant head circumference (trajectories) From health records Infant age 3 months
Secondary Infant total body mass (trajectories) From health records Infant age 6 months
Secondary Infant length (trajectories) From health records Infant age 6 months
Secondary Infant head circumference (trajectories) From health records Infant age 6 months
Secondary Infant total body mass (trajectories) From health records Infant age 8 months
Secondary Infant length (trajectories) From health records Infant age 8 months
Secondary Infant head circumference (trajectories) From health records Infant age 8 months
Secondary Infant total body mass (trajectories) From health records Infant age 10 months
Secondary Infant length (trajectories) From health records Infant age 10 months
Secondary Infant head circumference (trajectories) From health records Infant age 10 months
Secondary Infant total body mass (trajectories) From health records Infant age 12 months
Secondary Infant height (trajectories) From health records Infant age 12 months
Secondary Infant head circumference (trajectories) From health records Infant age 12 months
Secondary Infant total body mass (trajectories) From health records Infant age 24 months
Secondary Infant height (trajectories) From health records Infant age 24 months
Secondary Infant head circumference (trajectories) From health records Infant age 24 months
Secondary Infant gut microbiota Sequencing 0 to 4 weeks
Secondary Infant gut microbiota Sequencing 0 to 8 weeks
Secondary Infant microRNA Sequencing 0 to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2